A colorectal cancer pathology report can contain technical terms, including MSI, or microsatellite instability, and dMMR, or mismatch repair deficiency. MSI and MMR testing in Malaysia helps your care team understand tumour biology, assess inherited cancer risk, and discuss whether immunotherapy may be relevant.
These results don’t independently select treatment. Your colon cancer stage, tumour location, scans, surgery options, overall health, and specialist assessment still shape the treatment plan.
Quick Answer
MSI and MMR tests are tumour tests performed on colorectal cancer tissue, often from a biopsy or surgery specimen. They measure microsatellite instability and can identify tumours with deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H), also called MSI-High. These results may raise questions about inherited Lynch syndrome and make immunotherapy relevant in advanced disease, but they don’t guarantee a response or a particular treatment. Tumour testing is not the same as inherited genetic testing.
A proficient mismatch repair (pMMR) or microsatellite stable (MSS) result is also useful. It helps your oncologist narrow down the cancer treatment options that fit your clinical situation. However, a normal tumour result does not remove all inherited or personal cancer risk, especially when you have a strong family history.
Key Takeaways
- MSI and MMR testing examines the cancer tissue, not the genes you were born with.
- A dMMR or MSI-H result can lead to discussions about Lynch syndrome assessment and immunotherapy.
- IHC and PCR-based MSI testing assess related features in different ways, and they usually agree but are not identical.
- Malaysian research from Kuantan found strong agreement between the two methods, while still identifying occasional differing results.
- A pathology report, imaging, cancer stages, and your wider medical history all matter when your specialist discusses colorectal cancer treatment.
MSI MMR Testing Malaysia: What the Terms Mean
DNA mismatch repair is a natural system that corrects small copying errors when cells divide. If a colorectal tumour loses this repair ability, DNA errors can build up. This is called mismatch repair deficiency, or dMMR.
Microsatellites are short, repeated DNA sections. Some MSI assays examine repeated markers, including mononucleotide markers. When mismatch repair fails, these regions can change in length. This is called microsatellite instability, and the tumour may be described as MSI-H.
dMMR and MSI-H often describe the same biological problem
Although the labels differ, dMMR and MSI-H often identify tumours with impaired DNA repair. A tumour can also be pMMR, meaning its mismatch repair proteins appear retained, or MSS, meaning microsatellite stable.
Your report may describe dMMR pMMR status by stating whether MMR proteins are lost or retained. It may use one set of terms or both. Neither result confirms how aggressive the cancer is, whether it has spread, or which treatment you should receive. It adds one piece to a larger cancer diagnosis.
Why testing is now widely discussed
International clinical guidelines support MMR or MSI testing for newly diagnosed colorectal cancers. The College of American Pathologists guidance on MMR and MSI testing explains its role in immune checkpoint inhibitor decisions and Lynch syndrome evaluation.
In Malaysia, your hospital’s testing pathway may vary. Ask whether testing has been completed, which method the laboratory used, and whether any follow-up is needed.
How IHC and PCR-Based MSI Testing Differ
Pathologists commonly use immunohistochemistry, called IHC, or a DNA-based PCR test. Both methods use tumour material, yet they answer the question from different directions.
Immunohistochemistry checks four mismatch repair proteins
IHC uses immunohistochemical staining to display the four separate mismatch repair proteins, MLH1 MSH2 MSH6 PMS2, in tumour cells. When one or more proteins are absent, the result can support a finding of dMMR.
This method also gives the pathologist a clue about which repair pathway may be affected. Internal healthy cells in the tissue act as controls. If those cells stain correctly but tumour cells do not, the finding is more reliable.
PCR looks for DNA instability
PCR-based MSI testing compares repeated DNA areas in tumour tissue, usually against normal tissue or an established testing approach. It detects microsatellite instability, the DNA changes that can occur when mismatch repair is not working properly.
Some laboratories use panels of mononucleotide markers, such as BAT-25 BAT-26 and NR-21 NR-24. Depending on the laboratory, testing may involve PCR capillary electrophoresis or a Promega MSI analysis system. A Promega panel can include mononucleotide markers such as MONO-27, but this doesn’t mean every Malaysian laboratory uses Promega.
Different laboratories may use different marker panels. Variations in the number and type of mononucleotide markers can sometimes produce slightly different classifications.
The report generally classifies the tumour as MSI-H, MSS, or occasionally MSI-low. MSS means microsatellite stable, with no meaningful instability detected by that assay.
IHC shows whether repair proteins are present. PCR measures the DNA instability that can result when repair fails.
Why Results Can Occasionally Differ
IHC and PCR usually point in the same direction, but neither test is flawless. A small or damaged biopsy sample, low tumour content, technical issues, and uncommon gene changes can make interpretation harder. PCR-based classification may also be influenced by marker selection, mononucleotide markers, and laboratory factors.
Pathologists review unexpected staining carefully
A tumour may show patchy, weak, or heterogeneous immunohistochemical staining rather than clear protein loss. In that situation, pathologists consider tissue quality, internal controls, staining patterns, and the clinical context.
They may repeat a stain, test another tumour block, or request a different method. This is why a single word in a report shouldn’t be interpreted without the pathologist and treating specialist.
Discordance may need confirmation
A tumour can rarely show microsatellite instability (MSI-H) with retained MMR protein staining, or show protein loss while PCR indicates MSS. The College of American Pathologists discussion of discordant MMR and MSI results describes why repeat or independent testing can be appropriate.
If your result seems unclear, ask whether the pathology department recommends further review. A cancer treatment plan review can also help you understand whether all relevant pathology and molecular findings have been considered.
What Malaysian Colorectal Cancer Studies Show
Local research supports the practical use of both testing approaches. It also shows why results need expert interpretation rather than automatic assumptions.
A 2024 Kuantan study found strong agreement
A 2024 study by Faizee MI and colleagues reviewed 123 colorectal cancer cases in Kuantan, Pahang. IHC identified dMMR in 14 cases, or 11.4 percent. In a 50-case subset assessed through MSI analysis, 13 cases showed high microsatellite instability, or MSI-H.
The methods showed a high concordance rate, with a kappa value of 0.896. However, two of the 50 tested cases had differing results. The published Malaysian concordance study supports using both methods thoughtfully rather than treating either as an absolute answer.
Different studies can report different agreement levels
An earlier Malaysian study from 2019 reported substantial agreement, with a kappa value of 0.639. Different patient groups, sample sizes, laboratory methods, and interpretation rules can affect study findings.
These kappa values reflect agreement between methods in each study, not a national Malaysian testing rate. Still, they show that IHC and PCR-based MSI analysis usually align, while exceptions deserve careful pathology review.
When Tumour Testing Raises Lynch Syndrome Questions
Lynch syndrome is an inherited condition that increases the risk of colorectal cancer and several other cancers. It is linked to inherited changes in mismatch repair genes.
Tumour testing is not inherited genetic testing
An MSI-H or dMMR result can raise suspicion of Lynch syndrome, but it does not confirm an inherited condition. Some colorectal tumours develop MMR changes only within the cancer cells and are not passed through families.
If a result is unexplained, your doctor may suggest genetic counselling and germline testing. The approach may include a broader panel or next-generation sequencing, based on genetic counselling and specialist assessment. The NCI overview of colorectal cancer genetics explains that MSI in a tumour can be a hallmark of Lynch syndrome, while further assessment is needed to establish inherited risk.
Family history still matters after a normal result
Tell your doctor about relatives with colorectal, uterine, ovarian, stomach, urinary tract, pancreatic, or certain other cancers. The age at diagnosis and the number of affected relatives matter.
A pMMR or MSS tumour makes Lynch syndrome less likely in many situations, but it doesn’t rule out every inherited cancer risk. Your doctor may still recommend genetic counselling when your personal or family history is concerning.
How MSI and MMR Results Affect Treatment Discussions
For early colorectal cancer, surgery, pathology findings, and cancer stage often guide the main treatment discussion. MSI and MMR status may add prognostic information and become particularly important for unresectable or metastatic colorectal cancer.
Immunotherapy may be considered for MSI-H or dMMR disease
Checkpoint inhibitors help the immune system recognise and attack cancer cells. Pembrolizumab, also called Keytruda (pembrolizumab), is one option for certain people with unresectable or metastatic MSI-H or dMMR colorectal cancer.
MSI-H is also called MSI-High. These findings may help doctors assess whether immunotherapy is worth discussing, but they can’t predict an individual immunotherapy response.
The NCI update on immunotherapy for dMMR colorectal cancer notes that pembrolizumab is already approved as an initial treatment for advanced dMMR colorectal cancer in the United States. For metastatic colorectal cancer, treatment evidence, approval, funding, and availability can differ in Malaysia.
pMMR or MSS results lead to a different conversation
Most colorectal cancers are pMMR or MSS. These results don’t mean there are no treatment options. Depending on the full picture, treatment can include cancer surgery, chemotherapy, radiotherapy for some rectal cancers, targeted therapy, or other approaches.
Other molecular findings, such as tumor mutation burden, may sometimes influence whether targeted therapy is discussed. They don’t replace MSI or MMR testing, and suitability depends on your scans, pathology, cancer stage, previous treatment, symptoms, and overall health.
To prepare for a specialist discussion, you can Explore Cancer Treatment Options for information and medical-travel coordination support. It doesn’t provide diagnosis or direct treatment, and it isn’t a substitute for an oncology consultation.
Preparing for a Report Review or Medical Second Opinion
Keep copies of your colonoscopy report, biopsy report, MMR or MSI result, scan reports, scan images, blood results, referral letters, and treatment summary. Complete records help another specialist understand the testing sequence and treatment recommendations.
Questions to ask your oncologist or pathologist
- Has my tumour had IHC, PCR-based MSI testing, or both?
- Does my report say dMMR, pMMR, MSI-H, MSS, or an unclear result?
- Do my result and family history suggest genetic counselling?
- Could this finding affect surgery, chemotherapy, immunotherapy, or targeted therapy discussions?
- Were all relevant treatment options and molecular findings considered?
- Would repeat testing or a pathology review help clarify the result?
A second opinion can clarify, not replace, your care team
A cancer treatment second opinion may confirm the current diagnosis and treatment plan. It can also clarify an uncertain result, review pathology and molecular reports, or identify whether further assessment is medically appropriate. It doesn’t imply that your original doctor was wrong.
For help organising records for an external review, Explore Medical Report Review Support. If you want an oncology second opinion, Explore Cancer Second Opinion Support for coordination assistance. AGH Medical is not a doctor, hospital, oncologist, or direct treatment provider, and these services don’t diagnose cancer or replace advice from your treating specialist.
Frequently Asked Questions
Does an MSI-H result mean I definitely have Lynch syndrome?
No. MSI-H or dMMR tumour results can lead to Lynch syndrome assessment, but they don’t prove an inherited condition. Genetic counselling and germline testing may be needed.
Is PCR more accurate than IHC?
Neither test is automatically better in every case. IHC identifies missing repair proteins, while PCR measures microsatellite instability in DNA. Some PCR panels use mononucleotide markers or other marker sets. The tests usually agree, but doctors may use another method when results don’t match.
Can I receive immunotherapy because my tumour is MSI-H?
MSI-H or dMMR status can make immunotherapy relevant, particularly for unresectable or metastatic colorectal cancer. Your oncologist must still assess your cancer stage, prior treatment, other health conditions, and local treatment access. A microsatellite stable or pMMR result doesn’t eliminate every treatment possibility, but it may affect which options are considered.
Should I seek a medical second opinion?
A medical second opinion may be useful if your pathology result is unclear, you have a strong family history, or you want a cancer treatment plan review. A report review may also consider whether relevant molecular findings, including options such as targeted therapy, were addressed. It may confirm the original recommendation as often as it changes or adds to it.
Clear Results Support Better Decisions
MSI and MMR testing gives you and your care team more information about the tumour’s DNA repair system, inherited-risk questions, and possible treatment pathways. It is most useful when read alongside the full pathology report, scans, cancer stage, and your personal health needs.
Keep your records together, ask for plain-language explanations, and discuss any uncertainty with your treating team. A well-interpreted result supports informed decisions without replacing specialist judgement.
Medical disclaimer: This content is for general educational purposes only and may not apply to every patient. It is not medical advice, a diagnosis, or a treatment recommendation. Consult your own doctor, oncologist, or qualified healthcare professional before making medical decisions.
